Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q1 2025 value amounting to 6984.3%.

  • Rani Therapeutics Holdings' EBIT Margin changed N/A to 6984.3% in Q1 2025 from the same period last year, while for Sep 2025 it was 3727.75%, marking a year-over-year decrease of 77239700.0%. This contributed to the annual value of 5186.19% for FY2024, which is N/A changed from last year.
  • Rani Therapeutics Holdings' EBIT Margin amounted to 6984.3% in Q1 2025.
  • In the past 5 years, Rani Therapeutics Holdings' EBIT Margin ranged from a high of 1445.02% in Q2 2023 and a low of 6984.3% during Q1 2025
  • Over the past 4 years, Rani Therapeutics Holdings' median EBIT Margin value was 384.22% (recorded in 2023), while the average stood at 523.54%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 53818700bps in 2021, then plummeted by -24916300bps in 2024.
  • Quarter analysis of 4 years shows Rani Therapeutics Holdings' EBIT Margin stood at 268.13% in 2021, then skyrocketed by 487bps to 1036.57% in 2023, then plummeted by -240bps to 1455.06% in 2024, then tumbled by -380bps to 6984.3% in 2025.
  • Its EBIT Margin was 6984.3% in Q1 2025, compared to 1455.06% in Q4 2024 and 1036.57% in Q4 2023.